Effects of Serenoa repens Alcohol Extract on Benign Prostate Hyperplasia

1. Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med. 2008; 121(8 Suppl 2):S3-10. doi: 10.1016/j.amjmed.2008.05.021.10.1016/j.amjmed.2008.05.021Open DOISearch in Google Scholar

2. Patel ND, Parsons JK. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol. 2014; 30(2):170-6. doi: 10.4103/0970-1591.126900.10.4103/0970-1591.126900Open DOISearch in Google Scholar

3. Vuichoud C, Loughlin KR. Benign prostatic hyperplasia: epidemiology, economics and evaluation. Can J Urol. 2015; 22 Suppl 1:1-6.Search in Google Scholar

4. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1):5-16; discussion 16.10.1016/S0090-4295(01)01298-5Search in Google Scholar

5. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int. 2006; 97 Suppl 2:3-6; discussion 21-2. doi: 10.1111/j.1464-410X.2006.06097.x.10.1111/j.1464-410X.2006.06097.xOpen DOISearch in Google Scholar

6. Barkin J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol. 2011; 18 Suppl:14-9.Search in Google Scholar

7. Alcaraz A, Carballido-Rodriguez J, Unda-Urzaiz M, et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study. Int Urol Nephrol. 2016; 48(5):645-56. doi: 10.1007/s11255-015-1206-7.10.1007/s11255-015-1206-7Open DOISearch in Google Scholar

8. Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Ther Adv Urol. 2012; 4(2):77-83. doi: 10.1177/1756287212437361.10.1177/1756287212437361Search in Google Scholar

9. Fourcade RO, Lacoin F, Roupret M, et al. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World J Urol. 2012; 30(3):419-26. doi: 10.1007/s00345-011-0756-2.10.1007/s00345-011-0756-2Open DOISearch in Google Scholar

10. Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int. 2015; 94(2):187-93. doi: 10.1159/000366521.10.1159/000366521Search in Google Scholar

11. Di Silverio F, Monti S, Sciarra A, et al. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. Prostate. 1998; 37(2):77-83. doi: 10.1002/(SICI)1097-0045(19981001)37:2<77::AIDPROS3>3.0.CO;2-I.10.1002/(SICI)1097-0045(19981001)37:2<77::AIDPROS3>3.0.CO;2-Open DOISearch in Google Scholar

12. Bayne CW, Donnelly F, Ross M, et al. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH. Prostate. 1999; 40(4):232-41. doi: 10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0.10.1002/(SICI)1097-0045(19990901)40:4<232::AID-PROS4>3.0.CO;2-0Open DOISearch in Google Scholar

13. Latil A, Libon C, Templier M, et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012; 110(6 Pt B):E301-7. doi: 10.1111/j.1464-410X.2012.11144.x.10.1111/j.1464-410X.2012.11144.x22520557Search in Google Scholar

14. Scaglione F, Lucini V, Pannacci M, et al. Comparison of the potency of 10 different brands of Serenoa repens extracts. Eur Rev Med Pharmacol Sci. 2012; 16(5):569-74.Search in Google Scholar

15. Sirab N, Robert G, Fasolo V, et al. Lipidosterolic extract of Serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cells. Int J Mol Sci. 2013; 14(7):14301-20. doi: 10.3390/ijms140714301.10.3390/ijms140714301374224523846725Open DOISearch in Google Scholar

16. European Medicines Agency (2015) Committee on Herbal Medicinal Products (HMPC). Assessment report on Serenoa repens (W, Bartram) Small, fructus EMA/HMPC/137250/2013. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Herbal-HMPC_assessment_report/2014/12/WC500179593.pdf. Accessed May 2017.Search in Google Scholar

17. Gratzke C, Bachmann A, Descazeaud A, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015; 67(6):1099-109. doi: 10.1016/j.eururo.2014.12.038.10.1016/j.eururo.2014.12.03825613154Open DOISearch in Google Scholar

18. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003; 170(2 Pt 1):530-47. doi: 10.1097/01.ju.0000078083.38675.79.10.1097/01.ju.0000078083.38675.7912853821Open DOISearch in Google Scholar

19. Andriole GL, McCullum-Hill C, Sandhu GS, et al.; CAMUS Study Group. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013; 189(2):486-92. doi: 10.1016/j.juro.2012.09.037.10.1016/j.juro.2012.09.037397945123253958Open DOISearch in Google Scholar

20. Fagelman E, Lowe FC. Saw Palmetto Berry as a Treatment for BPH. Rev Urol. 2001 Summer; 3(3):134-8.Search in Google Scholar

21. Kim SW. Phytotherapy: emerging therapeutic option in urologic disease. Transl Androl Urol. 2012; 1(3):181-91. doi: 10.3978/j.issn.2223-4683.2012.05.10.10.3978/j.issn.2223-4683.2012.05.10470825026816707Open DOISearch in Google Scholar

22. Argirović A, Argirović D. Does the Addition of Serenoa Repens to Tamsulosin Improve Its Therapeutical Efficacy in Benign Prostatic Hyperplasia? Vojnosanit Pregl. 2013; 70(12):1091-6.10.2298/VSP110620029A24450252Search in Google Scholar

23. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011; 3(4):193-8. doi: 10.1177/1756287211418725.10.1177/1756287211418725317570321969849Search in Google Scholar

24. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. NEJM. 2006; 354(6):557-66. doi: 10.1056/NEJMoa053085.10.1056/NEJMoa05308516467543Open DOISearch in Google Scholar

25. Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA. 2011; 306(12):1344-51. doi: 10.1001/jama.2011.1364.10.1001/jama.2011.1364332634121954478Open DOISearch in Google Scholar

26. MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int. 2012; 109(12):1756-61. doi: 10.1111/j.1464-410X.2012.11172.x.10.1111/j.1464-410X.2012.11172.x351328222551330Open DOISearch in Google Scholar

27. Ooi SL, Pak SC. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and its Clinical Implications in Naturopathic Medicine. J Altern Complement Med. 2017 Apr 24. doi: 10.1089/acm.2016.0302.10.1089/acm.2016.030228436684Open DOISearch in Google Scholar

28. Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009; 30(3):227-81. doi: 10.1038/aps.2009.1.10.1038/aps.2009.1400240219262550Open DOISearch in Google Scholar

29. De Monte C, Carradori S, Granese A, et al. Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol. 2014; 14:63. doi: 10.1186/1471-2490-14-63.10.1186/1471-2490-14-63413642025112532Open DOISearch in Google Scholar

30. Agbabiaka TB, Pittler MH, Wider B, et al. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009; 32(8):637-47. doi: 10.2165/00002018-200932080-00003.10.2165/00002018-200932080-0000319591529Search in Google Scholar